Abstract
The Unique Role That WHO Could Play in Implementing Phage Therapy to Combat the Global Antibiotic Resistance Crisis.
Highlights
Given the immensity of the global antimicrobial resistance (AMR) crisis, new avenues complementary to traditional antibiotics are urgently needed, in developing countries where 90% of the predicted AMR deaths will occur (O’Neil, 2014)
Phage therapy is undergoing a renaissance in industrialized countries, though their use has been little explored for low-income and lower-middle-income countries (LMICs)
World Health Organization (WHO) could be a valuable resource to compensate for the shortcomings of knowledge, technology, and regulatory skill associated with the limited incomes fueled by phage therapy
Summary
Given the immensity of the global antimicrobial resistance (AMR) crisis, new avenues complementary to traditional antibiotics are urgently needed, in developing countries where 90% of the predicted AMR deaths will occur (O’Neil, 2014). Bacteriophages ( known as phages) are a class of natural antimicrobials that were used, sometimes successfully (Abedon et al, 2011), before chemical antibiotics were discovered, and in recent years phages have been utilized to treat antibiotic-resistant infections (Kortright et al, 2019). Rehabilitation of phage therapy represents both challenges and opportunities, which need to be dealt with at both local and global levels. The World Health Organization (WHO) appears uniquely positioned to play a key role in the deployment of this atypical but promising technology as a means to combat antibiotic resistance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
